Skip to content

US · ANNX · BIOTECHNOLOGY

Annexon, Inc. (ANNX) intrinsic value and stock valuation

$3.10as of 2026-11-21 · Mkt cap 879.83M

Data updated · price as of 2026-11-21

IC valuationIntrinsic value, upside vs price and the fair-value band are available to Pro members.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Annexon, Inc. DCF and intrinsic value

InvestorsCraft values ANNX with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from ANNX’s statements →

Annexon, Inc. Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Biotechnology Brisbane, CA 94005 annexonbio.com

How the business is doing

Fiscal 2017–2025, USD

Revenue
$0.00
20172025
Net income
-$-206.69M
20172025
Free cash flow
-$-186.49M
20172025
Total equity
$211.7M-9.3% 5y CAGRd
20172025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2017–2025, USD
20252024202320222021
Revenue$0.00$0.00$0.00$0.00$0.00
Operating income-$-216.41M-$-154.07M-$-143.72M-$-145.6M-$-130.71M
Net income-$-206.69M-$-138.2M-$-134.24M-$-141.95M-$-130.32M
EPSd-$-1.33M-$-1.01M-$-1.77M-$-2.6M-$-3.4M
Operating cash flow-$-186.36M-$-118.01M-$-121.14M-$-116.31M-$-106.11M
Capital expenditure-$-140K-$-10K-$-190K-$-6.53M-$-1.65M
Free cash flow-$-186.49M-$-118.02M-$-121.33M-$-122.83M-$-107.76M
Total assets$277.6M$350.1M$297.7M$285.1M$287M
Total debt$26.2M$29M$31.4M$32.9M$34.6M
Net debt-$-135.85M-$-20.53M-$-193.75M-$-107.16M-$-40.25M
Total equity$211.7M$293.1M$250.6M$231.2M$231.9M
Cash and short-term investments$238.3M$312M$259.7M$242.7M$242.7M
Income statement
20252024202320222021
Revenue$0.00$0.00$0.00$0.00$0.00
Cost of revenue$3.69M$3.45M$0.00$0.00$0.00
Gross profit-$-3.69M-$-3.45M$0.00$0.00$0.00
Research and development expenses$184.7M$119.5M$113.8M$112.5M$100.1M
Selling, general and administrative expenses$31.7M$34.6M$28M$31M$30.7M
Other expenses-$-3.69M-$-3.45M$1.95M$2.15M$0.00
Operating expenses$212.7M$150.6M$143.7M$145.6M$130.7M
Cost and expenses$216.4M$154.1M$143.7M$145.6M$130.7M
Interest income$9.72M$15.9M$9.49M$3.65M$390K
Interest expense$0.00$0.00$0.00$0.00$0.00
Depreciation and amortization$2.65M$3.45M$2.15M$2.15M$2.14M
Ebitda-$-204.04M-$-134.75M-$-132.09M-$-139.79M-$-128.18M
Operating income-$-216.41M-$-154.07M-$-143.72M-$-145.6M-$-130.71M
Total other income/expenses, net$9.72M$15.9M$9.49M$3.65M$390K
Income before tax-$-206.69M-$-138.2M-$-134.24M-$-141.95M-$-130.32M
Income tax expense$0.00$0.00$0.00$0.00$0.00
Net income-$-206.69M-$-138.2M-$-134.24M-$-141.95M-$-130.32M
Weighted average shares outstanding$155.1M$137.4M$75.7M$54.7M$38.3M
Weighted average diluted shares outstanding$155.1M$137.4M$75.7M$54.7M$38.3M
Balance sheet
20252024202320222021
Cash and short-term investments$238.3M$312M$259.7M$242.7M$242.7M
Net receivables$0.00$0.00$0.00$0.00$0.00
Inventory$0.00$0.00$0.00$0.00$0.00
Total current assets$242.2M$316.5M$263.9M$248.1M$247.7M
Property, plant and equipment, net$25.8M$29.3M$32.8M$36M$38.2M
Goodwill and intangible assets$0.00$0.00$0.00$0.00$0.00
Long-term investments$0.00$0.00$0.00$1.03M$0.00
Total non-current assets$35.4M$33.6M$33.8M$37M$39.4M
Total assets$277.6M$350.1M$297.7M$285.1M$287M
Accounts payable$14.9M$10.4M$5.49M$7.42M$11.2M
Short-term debt$2.91M$2.52M$2.17M$1.32M$1.2M
Deferred revenue$0.00$0.00$0.00$0.00$0.00
Total current liabilities$42.6M$30.5M$17.9M$22.4M$21.7M
Long-term debt$23.3M$26.5M$29.2M$31.5M$33.4M
Deferred revenue, non-current$0.00$0.00$0.00$0.00$0.00
Total non-current liabilities$23.3M$26.5M$29.2M$31.5M$33.4M
Capital lease obligations$26.2M$29M$31.4M$32.9M$34.6M
Total liabilities$65.9M$57M$47.1M$53.9M$55.1M
Common stock$150K$110K$80K$50K$40K
Retained earnings-$-917.39M-$-710.7M-$-572.5M-$-438.26M-$-296.31M
Accumulated other comprehensive income (loss)-$-30K$10K-$-50K-$-370K-$-180K
Total equity$211.7M$293.1M$250.6M$231.2M$231.9M
Total investments$76.3M$262.5M$34.6M$103.7M$167.9M
Total debt$26.2M$29M$31.4M$32.9M$34.6M
Net debt-$-135.85M-$-20.53M-$-193.75M-$-107.16M-$-40.25M
Cash flow statement
20252024202320222021
Net income-$-206.69M-$-138.2M-$-134.24M-$-141.95M-$-130.32M
Depreciation and amortization$2.17M$2.15M$2.15M$2.11M$3.41M
Stock-based compensation$16.4M$19.4M$18.2M$18.5M$0.00
Change in working capital$4.23M$6.36M-$-5.8M$3.74M$3.28M
Accounts receivable$0.00$0.00$0.00$0.00$0.00
Inventory$0.00$0.00$0.00$0.00$0.00
Accounts payable$4.49M$4.94M-$-2.08M-$-290K$3.86M
Net cash provided by operating activities-$-186.36M-$-118.01M-$-121.14M-$-116.31M-$-106.11M
Investments in property, plant and equipment-$-140K-$-10K-$-190K-$-6.53M-$-1.65M
Acquisitions, net$0.00$0.00$0.00-$-60K$0.00
Net cash used for investing activities$190.1M-$-218.8M$70.7M$58.4M-$-88.24M
Common stock issued$110.5M$161.9M$135.5M$130.5M$1.79M
Common stock repurchased$0.00$0.00$0.00$0.00$0.00
Dividends paid-$-1.86M$0.00$0.00$0.00$0.00
Net cash used for financing activities$108.9M$161.2M$135.5M$122.9M$1.79M
Net change in cash$112.6M-$-175.61M$85.1M$65M-$-193.72M
Cash at end of period$163.1M$50.5M$226.1M$141.1M$74.8M
Operating cash flow-$-186.36M-$-118.01M-$-121.14M-$-116.31M-$-106.11M
Capital expenditure-$-140K-$-10K-$-190K-$-6.53M-$-1.65M
Free cash flow-$-186.49M-$-118.02M-$-121.33M-$-122.83M-$-107.76M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Annexon, Inc.

        Annexon, Inc. is a biopharmaceutical company currently engaged in clinical trials, dedicated to the discovery and advancement of therapies for a variety of autoimmune, neurodegenerative, and ophthalmic conditions. Central to its approach is the C1q molecule, which initiates the classical complement pathway. The company targets this pathway to address specific disease mechanisms, such as those seen in antibody-mediated autoimmune disorders and complement-driven neurodegeneration. The company's developmental pipeline features several promising candidates. ANX005, a monoclonal antibody, is in advanced clinical testing, undergoing Phase II/III trials for Guillain-Barré syndrome, as well as Phase II trials for warm autoimmune hemolytic anemia, Huntington's disease, and amyotrophic lateral sclerosis. Another candidate, ANX009, is currently in Phase Ib studies for lupus nephritis. Additionally, ANX007 is progressing through Phase II clinical trials for the treatment of geographic atrophy, an eye disease. Further investigational assets include ANX105, a monoclonal antibody being developed for neurodegenerative indications, and ANX1502, an oral small molecule under investigation for specific autoimmune conditions. Annexon, Inc. was established in 2011 and operates from its headquarters in Brisbane, California.

        CEO
        Douglas E. Love
        Employees
        96
        Beta
        1.17

        Explore

        Frequently asked questions

        What is the intrinsic value of Annexon, Inc. (ANNX)?

        InvestorsCraft does not currently publish an intrinsic value for ANNX. How the IC value is calculated.

        Is ANNX undervalued?

        InvestorsCraft does not publish an undervaluation signal for ANNX at this time.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.